Both in Biotechnology
Cullinan Therapeutics vs Prime Medicine
Over the past year CGEM returned +68.8% and PRME returned +15.6%; their daily moves had a correlation of 0.38.
CGEM +68.8% PRME +15.6%Growth of $1, one year, split-adjusted
| Metric | CGEM | PRME |
|---|---|---|
| Price | $12.49 | $4.97 |
| Market cap | $803.8M | $901.4M |
| Today | −20.70% | +9.23% |
| 1 month | −23.1% | +42.0% |
| 6 months | −16.7% | +45.7% |
| Year to date | +20.7% | +43.2% |
| 1 year | +59.9% | +9.0% |
| Revenue growth (YoY) | — | +3.5% |
| Gross margin | — | 100.0% |
| Net margin | — | −3649.0% |
| P/E (TTM) | — | — |
| Price / sales | — | 221.3× |
| Net cash | $334.5M | $95.1M |
| Dividend yield | — | — |
| Volatility (60d) | 87.7% | 112.8% |
| Short % of float | 14.3% | 34.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).